• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer.利用肿瘤动力学来阐明前列腺癌生化复发列线图中观察到的可变性。
Prostate. 2012 Feb;72(3):280-90. doi: 10.1002/pros.21429. Epub 2011 May 31.
2
Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?用于前列腺癌患者的GPSM评分算法在当代是否有效?
J Urol. 2007 Aug;178(2):459-63; discussion 463. doi: 10.1016/j.juro.2007.03.124. Epub 2007 Jun 11.
3
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.预测前列腺癌根治术后生化复发男性前列腺癌特异性死亡率的列线图
Eur Urol. 2015 Jun;67(6):1160-1167. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.
4
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.在极高危男性中,前列腺癌根治术前血液中激肽释放酶标志物的表现可预测术后早期复发和转移。
Prostate. 2020 Jan;80(1):51-56. doi: 10.1002/pros.23916. Epub 2019 Oct 11.
5
Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.将前列腺特异性抗原动力学纳入根治性前列腺切除术后挽救性放疗的当代预测nomogram 中。
Eur Urol Oncol. 2022 Jun;5(3):304-313. doi: 10.1016/j.euo.2021.04.011. Epub 2021 May 18.
6
Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.根治性前列腺切除术后精囊受累:进展的预测危险因素
Urology. 2003 Aug;62(2):304-9. doi: 10.1016/s0090-4295(03)00373-x.
7
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.临床局限性前列腺癌根治性前列腺切除术后的生化(前列腺特异性抗原)复发概率。
J Urol. 2003 Feb;169(2):517-23. doi: 10.1097/01.ju.0000045749.90353.c7.
8
Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.磁共振成像多参数分析及系统活检对经磁共振成像靶向活检诊断前列腺癌患者根治性前列腺切除术后生化复发的预测价值
Eur Urol Oncol. 2020 Dec;3(6):739-747. doi: 10.1016/j.euo.2020.07.008. Epub 2020 Aug 23.
9
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.前列腺癌根治术后生化复发后,前列腺特异抗原(PSA)倍增时间作为临床进展的预测指标。
Mayo Clin Proc. 2001 Jun;76(6):576-81. doi: 10.4065/76.6.576.
10
Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?与仅依据生化复发相比,列线图在预测前列腺癌根治术后侵袭性复发方面是否更准确?
BJU Int. 2009 Mar;103(5):603-8. doi: 10.1111/j.1464-410X.2008.08118.x. Epub 2008 Nov 18.

引用本文的文献

1
Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach.前列腺特异性抗原变化在手术治疗后生化复发的挽救性放疗最后一周的预测价值:一种实用方法。
Cancer Rep (Hoboken). 2020 Dec;3(6):e1285. doi: 10.1002/cnr2.1285. Epub 2020 Sep 3.
2
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.在接受前列腺切除术或挽救性放疗治疗前列腺癌后 PSA 升高的患者中,用基于树突细胞的主动细胞免疫疗法(DCVAC/PCa)进行的 I/II 期试验。
Cancer Immunol Immunother. 2018 Jan;67(1):89-100. doi: 10.1007/s00262-017-2068-x. Epub 2017 Sep 25.

本文引用的文献

1
A cell kinetics model for prostate cancer and its application to clinical data and individual patients.前列腺癌的细胞动力学模型及其在临床数据和个体患者中的应用。
J Theor Biol. 2010 May 21;264(2):420-42. doi: 10.1016/j.jtbi.2010.02.023. Epub 2010 Feb 20.
2
Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy.三种最常用的术前模型预测前列腺癌根治术后生化复发的头对头比较。
Eur Urol. 2010 Apr;57(4):562-8. doi: 10.1016/j.eururo.2009.12.003. Epub 2009 Dec 10.
3
Cancer metabolism and the dynamics of metastasis.癌症代谢与转移的动态过程。
J Theor Biol. 2009 Feb 7;256(3):305-10. doi: 10.1016/j.jtbi.2008.10.008. Epub 2008 Oct 21.
4
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.一项针对激素难治性转移性前列腺癌男性患者的当代预后列线图:TAX327研究分析
Clin Cancer Res. 2007 Nov 1;13(21):6396-403. doi: 10.1158/1078-0432.CCR-07-1036.
5
Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?用于前列腺癌患者的GPSM评分算法在当代是否有效?
J Urol. 2007 Aug;178(2):459-63; discussion 463. doi: 10.1016/j.juro.2007.03.124. Epub 2007 Jun 11.
6
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.根治性前列腺切除术后前列腺特异性抗原复发时间与前列腺癌特异性死亡风险
J Urol. 2006 Oct;176(4 Pt 1):1404-8. doi: 10.1016/j.juro.2006.06.017.
7
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.预测前列腺癌根治术后10年复发概率的术后列线图。
J Clin Oncol. 2005 Oct 1;23(28):7005-12. doi: 10.1200/JCO.2005.01.867.
8
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.根治性前列腺切除术后生化复发后前列腺癌特异性死亡风险。
JAMA. 2005 Jul 27;294(4):433-9. doi: 10.1001/jama.294.4.433.
9
The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.加利福尼亚大学旧金山分校前列腺癌风险评估评分:根治性前列腺切除术后疾病复发的直接且可靠的术前预测指标。
J Urol. 2005 Jun;173(6):1938-42. doi: 10.1097/01.ju.0000158155.33890.e7.
10
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.根治性前列腺切除术或放射治疗后前列腺癌特异性死亡率的替代终点。
J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83. doi: 10.1093/jnci/djg043.

利用肿瘤动力学来阐明前列腺癌生化复发列线图中观察到的可变性。

Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer.

机构信息

Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA.

出版信息

Prostate. 2012 Feb;72(3):280-90. doi: 10.1002/pros.21429. Epub 2011 May 31.

DOI:10.1002/pros.21429
PMID:21630294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3188696/
Abstract

BACKGROUND

Nomograms for biochemical recurrence (BCR) of prostate cancer (PC) after radical prostatectomy can yield very different prognoses for individual patients. Since the nomograms are optimized on different cohorts, the variations may be due to differences in patient risk-factor distributions. In addition, the nomograms assign different relative scores to the same PC risk factors and rarely stratify for tumor growth rate.

METHODS

We compared BCR-free probabilities from the GPSM model with a cell kinetics (CK) model that uses the individual's tumor state and growth rate. We first created a cohort of 143 patients that reproduced the GPSM patient distribution in Gleason score, Prostate specific antigen (PSA), Seminal vesicle involvement and Margin status since they form the GPSM score. We then performed 143 CK calculations to determine BCR-free probabilities for comparison with the GPSM results for all scores and with four other prominent nomograms for a high-risk patient.

RESULTS

The BCR-free probabilities from the CK model agree within 10% with those from the GPSM study for all scores once the CK model parameters are stratified in terms of the GPSM risk factors and the PSA doubling time (PSADT). However, the probabilities from widely used nomograms vary significantly.

CONCLUSIONS

The CK model reproduces the observed GPSM BCR-free probabilities with a broad stratification of model parameters for PC risk factors and can thus be used to describe PC progression for individual patients. The analysis suggests that nomograms should stratify for PSADT to be predictive.

摘要

背景

前列腺癌根治术后生化复发(BCR)的列线图可为个体患者提供截然不同的预后预测。由于这些列线图是在不同的队列中优化的,因此这种差异可能是由于患者风险因素分布的不同。此外,这些列线图为相同的前列腺癌风险因素赋予不同的相对评分,且很少对肿瘤生长率进行分层。

方法

我们将 GPSM 模型的 BCR 无复发生存率与使用个体肿瘤状态和生长率的细胞动力学(CK)模型进行比较。我们首先创建了一个包含 143 名患者的队列,这些患者在 Gleason 评分、前列腺特异性抗原(PSA)、精囊侵犯和切缘状态方面复制了 GPSM 患者的分布,因为这些因素构成了 GPSM 评分。然后,我们进行了 143 次 CK 计算,以确定 BCR 无复发生存率,以便与 GPSM 结果的所有评分进行比较,并与另外四个用于高危患者的著名列线图进行比较。

结果

一旦 CK 模型参数根据 GPSM 风险因素和 PSA 倍增时间(PSADT)进行分层,CK 模型的 BCR 无复发生存率与 GPSM 研究的结果在 10%以内一致。然而,广泛使用的列线图的概率差异很大。

结论

CK 模型通过广泛的 PC 风险因素模型参数分层再现了观察到的 GPSM BCR 无复发生存率,因此可用于描述个体患者的前列腺癌进展情况。分析表明,列线图应该对 PSA 倍增时间进行分层以实现预测。